How much funding has Hua Medicine raised?

Hua Medicine has raised $212.5M in total funding, most recently a Series D round.

Who are Hua Medicine's investors?

Hua Medicine's investors include ARCH Venture Partners, Venrock, Blue Pool Capital, Frontline BioVentures, GIC, AVICT Global.

When was Hua Medicine founded?

Hua Medicine was founded in 2010.

Where is Hua Medicine headquartered?

Hua Medicine is headquartered in Shanghai, China.

What industry is Hua Medicine in?

Hua Medicine operates in Biotech, Healthcare.

How many employees does Hua Medicine have?

Hua Medicine has 51-200 employees.

Hua Medicine

IPO

Global innovation in diabetes care.

Public · Shanghai, China · Founded 2010 · $212.5M raised

Biotech

Healthcare

Headquarters: Shanghai
Employees: 51–200
Founded: 2010
Business Model: B2B
Website: huamedicine.com

Total Funding: $212.5M
Last Round: $117.4M Series DMar 2018
Rounds: 4
Type: Public

About

Hua Medicine is a clinical-stage biotech company focused on innovative therapies for type 2 diabetes and CNS disorders. Its lead product, HuaTangNing (dorzagliatin), a first-in-class glucokinase activator, was approved in China in 2022 for T2D patients, including those with renal impairment.

Summary

Hua Medicine is a Biotech company based in Shanghai, China, founded in 2010. It has raised $212.5M in total across 4 rounds, most recently a $117.4M Series D round in Mar 2018. Investors include ARCH Venture Partners, Venrock and Blue Pool Capital.